[Zkušební verze zařízení, které není schváleno nebo schváleno americkým FDA] (INNOVATE)
The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
The INNOVATE Trial is a prospective, non-blinded, randomized, controlled, multi-center, non-inferiority study to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3™ (HM3) LVAS (Abbott) when used for the treatment of advanced, refractory left ventricular heart failure. It is the first clinical study to compare two left ventricular assist devices (LVAD) that belong to the same category of fully magnetically levitated LVAD.
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
Alabama
-
Birmingham, Alabama, Spojené státy, 35233
- University of Alabama at Birmingham Hospital
-
-
Arkansas
-
Little Rock, Arkansas, Spojené státy, 72205
- Baptist Health Medical Center-Little Rock
-
-
California
-
Los Angeles, California, Spojené státy, 90048
- Cedars-Sinai Medical Center
-
-
Florida
-
Gainsville, Florida, Spojené státy, 32608
- UF Health Shands Hospital
-
Orlando, Florida, Spojené státy, 32803
- Advent Health
-
-
Georgia
-
Atlanta, Georgia, Spojené státy, 30322
- Emory University
-
Atlanta, Georgia, Spojené státy, 30309
- Piedmont Healthcare
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60611
- Northwestern University
-
Chicago, Illinois, Spojené státy, 60637
- University of Chicago
-
Chicago, Illinois, Spojené státy, 60453
- Advocate Christ Medical Center
-
-
Indiana
-
Indianapolis, Indiana, Spojené státy, 46260
- Ascension St. Vincent Hospital - Indianapolis
-
-
Kansas
-
Kansas City, Kansas, Spojené státy, 66160
- The University Of Kansas Medical Center
-
-
Kentucky
-
Lexington, Kentucky, Spojené státy, 40536
- University of Kentucky
-
Louisville, Kentucky, Spojené státy, 40202
- University of Louisville
-
-
Maryland
-
Baltimore, Maryland, Spojené státy, 21201
- University of Maryland Medical Center
-
Baltimore, Maryland, Spojené státy, 21287
- The Johns Hopkins Hospital
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Spojené státy, 02111
- Tufts Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, Spojené státy, 48109
- University of Michigan
-
Detriot, Michigan, Spojené státy, 48202
- Henry Ford Health
-
Grand Rapids, Michigan, Spojené státy, 49503
- Corewell Health Grand Rapids Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, Spojené státy, 55455
- University of Minnesota
-
Minneapolis, Minnesota, Spojené státy, 55407
- Abbott Northwestern Hospital
-
-
Missouri
-
St Louis, Missouri, Spojené státy, 63110
- WashU Medicine
-
-
Nebraska
-
Omaha, Nebraska, Spojené státy, 68198
- University of Nebraska Medical Center
-
-
New Jersey
-
Newark, New Jersey, Spojené státy, 07112
- Newark Beth Israel Medical Center
-
-
New York
-
New York, New York, Spojené státy, 10065
- Weill Cornell Medicine
-
New York, New York, Spojené státy, 10016
- NYU Langone Health
-
New York, New York, Spojené státy, 10029
- Mount Sinai
-
New York, New York, Spojené státy, 10032
- Columbia University Irving Medical Center/ New York Presbyterian Hospital
-
The Bronx, New York, Spojené státy, 10467
- Montefiore Medical Center
-
-
North Carolina
-
Durham, North Carolina, Spojené státy, 27710
- Duke University
-
-
Ohio
-
Cincinnati, Ohio, Spojené státy, 45219
- The Christ Hospital - Cincinnati
-
Cleveland, Ohio, Spojené státy, 44195
- Cleveland Clinic
-
-
Oregon
-
Portland, Oregon, Spojené státy, 97239
- Oregon Health & Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19107
- Thomas Jefferson University Hospital
-
-
South Carolina
-
Charleston, South Carolina, Spojené státy, 29425
- Medical University of South Carolina
-
-
Tennessee
-
Memphis, Tennessee, Spojené státy, 38120
- Baptist - Memphis (Stern)
-
-
Texas
-
Dallas, Texas, Spojené státy, 75246
- Baylor University Medical Center, part of Baylor Scott & White Health
-
Dallas, Texas, Spojené státy, 75390
- UT southwestern Medical Center
-
Houston, Texas, Spojené státy, 77030
- Houston Methodist Hospital
-
Houston, Texas, Spojené státy, 77030
- Memorial Hermann-Texas Medical Center
-
Houston, Texas, Spojené státy, 77030
- Texas Heart Institute at Baylor St. Luke's Medical Center
-
Plano, Texas, Spojené státy, 75093
- Baylor Scott & White Medical Center - Plano
-
-
Utah
-
Salt Lake City, Utah, Spojené státy, 84132
- University of Utah
-
-
Virginia
-
Falls Church, Virginia, Spojené státy, 22042
- Inova Fairfax Medical Campus
-
-
Wisconsin
-
Milwaukee, Wisconsin, Spojené státy, 53215
- Aurora St. Luke's Medical Center
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Patient is ≥ 18 years of age.
-
Patient has received institutional approval for LVAD implantation.
-
Patient has a body surface area (BSA) ≥ 1.2 m2.
-
Patient is classified as NYHA Class IV with advanced heart failure refractory to advanced heart failure management or NYHA Class III with dyspnea upon mild physical activity.
-
Patient has a left ventricular ejection fraction (LVEF) ≤ 25% or LVEF < 30% on inotropes or temporary MCS.
-
Patient is inotrope dependent, OR has a cardiac index (CI) ≤ 2.2 liters/min/m2, while not on inotropes, and also meets one of the following criteria:
- Is on optimal medical management (OMM), based on current heart failure practice guidelines for at least 45 out of the last 60 days and is failing to respond or is not able to tolerate OMM; or
- Has advanced heart failure for at least 14 days and is dependent on an intra-aortic balloon pump (IABP) or temporary mechanical circulatory support device (MCSD) for at least seven days.
-
Patient has provided voluntary and informed consent.
-
Females of childbearing age agree to use adequate contraception and have a negative pregnancy test.
Exclusion Criteria:
-
Patient's heart failure etiology is related to restrictive or constrictive physiology (e.g., nondilated hypertrophic cardiomyopathy, cardiac amyloidosis/senile or other infiltrative disease), complex congenital heart disease (e.g., transposition of the great vessels), uncorrected thyroid disease, and/or pericardial disease.
-
Patient had a myocardial infarction within seven days of study enrollment.
-
Patient had cardiothoracic surgery within 30 days of implant with the exception of a procedure to implant temporary MCS: Impella 5.5, Impella CP or TandemHeart.
-
Patient has physiological conditions or comorbidities which pose high surgical risk or obstacles as determined by the Investigator.
-
Patient has contraindications to warfarin anticoagulation.
-
Patient has known hypo- or hypercoagulable state [e.g., disseminated intravascular coagulation (DIC)], or has a positive heparin-induced thrombocytopenia (HIT) assay and positive serotonin release assay or requires use of a non-heparin alternative anticoagulation strategy for cardiopulmonary bypass in the judgement of the Investigator.
-
Patient is on durable MCS (e.g., LVAD or RVAD).
-
Planned need for durable or temporary RVAD support concomitant with LVAD implant.
-
Patient is on any form of pre-implant temporary MCS other than isolated LVAD support with an intra-aortic balloon pump, Impella 5.5, Impella CP, or TandemHeart.
-
Patient is on any form of pre-implant temporary MCS and has a serum lactate dehydrogenase greater than 2.5 times the upper limits of normal or plasma free hemoglobin > 40 g/dL.
-
Patient has a history of organ transplantation.
-
Patient has a mechanical aortic valve that may not be converted to a bioprosthetic valve at the time of VAD implant.
-
Patient has a platelet count < 50 k/μl.
-
Patient has a history of confirmed untreated abdominal aortic aneurysm (AAA) > 5 cm in diameter.
-
Patient has moderate or severe aortic insufficiency that will not be corrected during the VAD implant procedure.
-
Patient has an uncontrolled systemic infection.
-
Patient has a positive COVID 19 test within 21 days of study enrollment and at least one high risk feature including need for supplemental oxygen or ferritin >1000 ug/L.
-
Patient has severe end-organ dysfunction as evidenced by one or more of the following criteria:
- Total bilirubin > 3.0 mg/dL or cirrhosis confirmed by liver imaging or hemodynamic assessment with or without biopsy confirmation.
- International normalized ratio (INR) ≥ 2.0 or PTT > 2.5 times control that is not related to anticoagulation therapy.
- Glomerular filtration rate (GFR) < 30 mL/ min/1.73 m2 or need for renal replacement therapy.
- Severe pulmonary arterial hypertension with a pulmonary vascular resistance (PVR) ≥ 8 Wood units that is not acutely reversible with pharmacologic intervention.
- Severe chronic obstructive pulmonary disease (COPD) or restrictive lung disease requiring home oxygen or an FEV1/FVC < 0.7 and FEV1 < 40% predicted.
- Mechanical ventilation for more than three days present at the time of study enrollment.
- Documented history of pulmonary embolism or pulmonary infarct within 60 days of study enrollment.
- History of stroke within 90 days of study enrollment or history of stroke with a mRS ≥ 3 at the time of study enrollment.
- Symptomatic cerebrovascular disease and/or uncorrected carotid stenosis > 80%.
- Significant peripheral vascular disease (PVD) accompanied by pain at rest or extremity ulceration.
- Pre-albumin < 15 mg/dL and/or albumin < 2.5 g/dL.
-
Patient has a non-cardiac comorbidity or illness that would limit survival to less than two years.
-
Patient has a psychiatric disease or disorder, or irreversible cognitive dysfunction, and/or insufficient social support or a history of non-adherence with medical instructions that is likely to impair study compliance.
-
Patient is participating in an interventional clinical trial that may impact or confound the results of the INNOVATE Trial.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: BrioVAD System
BrioVAD® Left Ventricular Assist System (BrioVAD® System) by BrioHealth Solutions, Inc. |
Implantation of the BrioVAD System to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 LVAS when used for the treatment of advanced, refractory, left ventricular heart failure. |
|
Aktivní komparátor: HeartMate 3
HeartMate 3 System by Abbott |
Implantation of the commercially approved HeartMate 3 LVAS, which is the standard treatment for advanced heart failure. |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Short-Term Indication Primary Endpoint
Časové okno: 6 months
|
Composite of survival to transplant, recovery or 6 months of LVAD support free of debilitating stroke [modified Rankin Scale (mRS) > 3], or reoperation to replace the pump |
6 months
|
|
Long-Term Indication Primary Endpoint
Časové okno: 24 months
|
Composite of survival to transplant, recovery or 24 months of LVAD support free of debilitating stroke (mRS > 3), or reoperation to replace the pump. |
24 months
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Powered Secondary Endpoint
Časové okno: 24 months
|
Total number of nights in hospital, skilled nursing facility, or inpatient rehabilitation, inclusive of index hospitalization, through 24 months post VAD implant, heart transplantation, VAD explant or decommission, study withdrawal, or death, whichever occurs first. |
24 months
|
|
Short-Term Indication Secondary Endpoint
Časové okno: 6 months
|
Evaluation of the short-term safety using INTERMACS adverse event (AE) terms and definitions through 6 months post VAD implant, heart transplantation, VAD explant or decommission, study withdrawal, or death, whichever occurs first. Incidences of all AEs and the event rate per patient year of support through 6 months will be reported. Differences in the event rates between the Study Arm and the Concurrent Control Arm will be analyzed. Serious adverse events (SAEs) will be analyzed in a similar manner. |
6 months
|
|
Long-Term Indication Secondary Endpoint
Časové okno: 24 months
|
Evaluation of the long-term safety using INTERMACS AE terms and definitions through 24 months post VAD implant, heart transplantation, VAD explant or decommission, study withdrawal, or death, whichever occurs first. Incidences of all AEs and the event rate per patient year of support through 24 months will be reported. Differences in the event rates between the Study Arm and the Concurrent Control Arm will be analyzed. SAEs will be analyzed in a similar manner |
24 months
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- CL-00545
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Protocol and data is company confidential.
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .